Highest-materiality recent filing
Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M
Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).
Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M
Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.
Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4
Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.
Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M
Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).
Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M
Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).
Biodesix shareholders approve reverse stock split ratio range 1:2 to 1:20
Shareholders approved reverse stock split of common stock at ratio between 1-for-2 and 1-for-20, as determined by board.
Biodesix Q1 revenue $18M (+21% YoY); revises FY2025 guidance to $80-85M
Total Q1 2025 revenue $18.0M (+21% YoY); diagnostic testing $16.3M (+18%), development services $1.7M (+61%).
Biodesix receives Nasdaq deficiency notice for bid price below $1.00 per share
Nasdaq notified Biodesix on March 24, 2025 that bid price closed below $1.00 for 30 consecutive business days.
Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M
FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.
Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint
Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.
Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY
Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).
Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M
Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).
Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M
Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).
On April 15, 2025, Charles Watts, M.D., a member of the Board of Directors (the “Board”) of Biodesix, Inc. (the “Company”), notified the Company of his intention to resign from his position as a director of the Board and as a member of the Compensation Committee, effective at the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 20, 2025.
Max materiality 0.85 · Median 0.68 · Most common event earnings